Physician profile
James Bromley
NPI 1255336996
$3,177.04
in general payments reported to CMS, 2019-2025
25 companies · $666 in 2025
The $666 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $197 · 2020: $170 · 2021: $437 · 2022: $632 · 2023: $431 · 2024: $644 · 2025: $666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,741.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,740.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $836.79 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Lilly USA, LLC | $497.13 | 2020-2025 | Zepbound, Mounjaro |
| Merck Sharp & Dohme LLC | $318.07 | 2019-2024 | Delstrigo, Dificid, Pifeltro |
| Janssen Biotech, INC. | $192.04 | 2019-2023 | Symtuza |
| Amgen INC. | $176.24 | 2021-2023 | Repatha, Otezla |
| Gilead Sciences, INC. | $134.19 | 2019-2023 | |
| Esperion Therapeutics, INC. | $116.29 | 2021 | |
| Pfizer INC. | $107.68 | 2024-2025 | |
| Theratechnologies INC. | $98.23 | 2019-2024 | Trogarzo, Egrifta |
| Horizon Therapeutics Plc | $92.38 | 2020-2022 | |
| Emd Serono, INC. | $84.26 | 2021-2024 | |
| Alk-Abello, INC | $63.51 | 2024 | Grastek, Ragwitek, Odactra |
| Boston Scientific Corporation | $60.74 | 2024-2025 | Watchman Flx, Watchman Access System |
| Antares Pharma, INC. | $60.68 | 2025 | Xyosted |
| Medtronic, INC. | $57.05 | 2025 | Symplicity G3 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acerus Pharmaceuticals Corporation | $55.74 | 2021-2022 | |
| Exact Sciences Corporation | $47.03 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $38.67 | 2024 | |
| Abbvie INC. | $30.83 | 2021 | |
| Tolmar, INC. | $28.31 | 2023-2025 | Jatenzo |
| Napo Pharmaceuticals INC | $26.48 | 2025 | Mytesi |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.32 | 2024 | Rejoyn |
| Glaxosmithkline, LLC. | $13.46 | 2025 | Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.39 | 2023 | Xifaxan |
| Novo Nordisk INC | $11.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Bromley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.